Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCYANK)

Drug Name
Doxapram Drug Info
Synonyms
Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI)
Therapeutic ClassCentral Nervous System Stimulants
Cross-matching ID
PubChem CID
3156
ChEBI ID
CHEMBL1754
CAS Number
CAS 309-29-5
TTD Drug ID
D0M7BT
INTEDE Drug ID
DR0541

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.20 0.00e+0 101/150 (67.33%) HSPA2;HNRNPU;HSPA8;...
Melanogenesis 2.16 0.00e+0 74/101 (73.27%) PRKCA;LEF1;GNAI1;...
Amoebiasis 2.05 0.00e+0 99/102 (97.06%) PRKCA;IL1B;TGFB1;...
Citrate cycle (TCA cycle) 1.88 1.53e-2 30/30 (100%) CS;SUCLG2;ACO2;...
Salivary secretion 1.86 1.46e-2 76/93 (81.72%) PRKCA;MUC5B;CST1;...
DNA replication 1.83 2.24e-2 34/36 (94.44%) RFC5;PCNA;MCM2;...
Vascular smooth muscle contraction 1.78 3.49e-2 113/133 (84.96%) PRKCA;MYH11;ACTG2;...
Glucagon signaling pathway 1.77 3.51e-2 89/107 (83.18%) CALML3;PYGM;FBP1;...
Gastric acid secretion 1.77 3.12e-2 63/76 (82.89%) CA2;PRKCA;GNAI1;...
Inflammatory mediator regulation of TRP channels 1.76 2.81e-2 82/98 (83.67%) PRKCA;SRC;IL1B;...
Amphetamine addiction 1.76 2.55e-2 57/69 (82.61%) PRKCA;CALML3;GRIA2;...
Platelet activation 1.75 2.54e-2 106/124 (85.48%) SRC;GNAI1;MYLK;...
Diabetic cardiomyopathy 1.75 2.35e-2 162/203 (79.8%) PRKCA;TGFB1;ATP5MC2;...
Neomycin, kanamycin and gentamicin biosynthesis 1.74 2.53e-2 5/5 (100%) HK3;HK2;HK1
AGE-RAGE signaling pathway in diabetic complications 1.74 2.44e-2 97/100 (97%) PRKCA;IL1B;TGFB1;...
Cell cycle 1.72 2.67e-2 110/124 (88.71%) TGFB1;PCNA;TFDP1;...
Wnt signaling pathway 1.71 3.30e-2 124/166 (74.7%) PRKCA;LEF1;FZD5;...
Oxytocin signaling pathway 1.71 3.12e-2 128/154 (83.12%) PRKCA;SRC;MEF2C;...
Type II diabetes mellitus 1.71 2.95e-2 42/46 (91.3%) IRS2;TNF;IRS1;...
Long-term depression 1.70 3.17e-2 55/60 (91.67%) PRKCA;GNAI1;ITPR1;...
Regulation of lipolysis in adipocytes 1.68 3.66e-2 52/55 (94.55%) IRS2;GNAI1;IRS1;...
Long-term potentiation 1.68 3.49e-2 61/67 (91.04%) PRKCA;CALML3;ITPR1;...
Dilated cardiomyopathy 1.68 3.34e-2 86/96 (89.58%) TPM2;TGFB1;DES;...
Axon guidance 1.66 3.97e-2 151/182 (82.97%) SEMA3C;PRKCA;SRC;...
Relaxin signaling pathway 1.64 4.59e-2 114/129 (88.37%) PRKCA;SRC;TGFB1;...
Legionellosis 1.63 4.88e-2 51/57 (89.47%) CYCS;HSPA2;IL1B;...
Adrenergic signaling in cardiomyocytes 1.62 4.97e-2 130/150 (86.67%) TPM2;PRKCA;GNAI1;...
Cocaine addiction 1.62 4.80e-2 42/49 (85.71%) GNAI1;GRIA2;SLC18A2;...
RNA transport 1.62 4.72e-2 128/186 (68.82%) EIF1AY;RAN;NUP107;...
Estrogen signaling pathway 1.61 4.57e-2 119/137 (86.86%) SRC;HSPA2;KRT17;...
Pentose and glucuronate interconversions -1.82 2.99e-2 17/34 (50%) AKR1A1;UGT2B4;UGDH;...
Mineral absorption -1.98 0.00e+0 48/60 (80%) FXYD2;SLC26A3;SLC34A2;...
Complement and coagulation cascades -2.02 0.00e+0 76/85 (89.41%) C6;MBL2;PROCR;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 10uM 24H